FDA committee finds no link between Tamiflu and deaths: AP

Share this article:
An FDA advisory committee determined today that the anti-flu drug Tamiflu is safe after finding no direct link between the drug and the deaths of 12 Japanese children who had taken it, the Associated Press reported.
"If we ever have a pandemic of avian flu, which is a debatable point, people want to know that they have a drug that will not cause more (harm) than the flu itself," said Robert Nelson, chairman of the FDA's Pediatric Advisory Committee. "There is no evidence that this will."
The committee was reported to have voted unanimously that no change was needed in the label to reflect the deaths of the Japanese children or other adverse affects. The committee did say that information should be added to the label about serious skin reactions.
The FDA is not bound by its advisory committee recommendations, but usually follows them.
Nelson added that the FDA should still be vigilant in going forward despite the finding that there was no reason for concern about the drug at this point. The committee asked the FDA staff to provide an update in about a year on any adverse reactions associated with Tamiflu. A full-report should be made in two years, the committee said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...